T-Rapa Cells as Novel Effector Cell Type for Chimeric Antigen Receptor Therapy
AssigneesThe Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
InventorsJeffrey A. Medin, Robyn A. Oldham, Daniel H. Fowler, Tania Felizardo
Life of this patent
Estimating the term…
Abstract
The present disclosure provides chimeric antigen receptor (CAR)-T-Rapa cells and methods of making and using them. Specifically, methods of producing T-Rapa cells that can express chimeric antigen receptors is provided.
Claims22
A method of making a T-Rapa cell expressing a chimeric antigen receptor (CAR) comprising the steps of:
- (a) conditioning ex vivo CD3+ T-cells with rapamycin to generate T-Rapa cells;
- and
- (b) transducing the T-Rapa cells in vitro with a vector that expresses the CAR to produce CAR-T-Rapa cells.
The method of any one of the preceding claims, wherein the purity of the CD3+ T-cells is at least 95%.
The method of any one of the preceding claims, wherein the vector is a lentiviral vector.
The method of any one of the preceding claims, wherein step (a) comprises culturing the T-cells in chemically defined medium comprising an effective amount of rapamycin to generate T-Rapa cells.
The method of any one of the preceding claims, wherein the CAR is a CAR specific to a tumor antigen.
The method of any one of the preceding claims, wherein the method further comprises maintaining and expanding the CAR-T-Rapa cells in in vitro culture and storing a portion of the CAR-T-Rapa cells for future administration to the subject.
A CAR-T-Rapa cell made by the method of any one of claims 1-14.
Dependencies are inferred from the claim text.